Figure 3.

PSMI by MG132 increases GFP-LC3-II levels in NRVMs. A, MG132 treatment inhibits proteasomal chy-motrypsin-like activity in NRVMs. NRVMs were treated with the indicated doses of MG132 for 12 hours. The cells were then harvested for proteasomal chymotrypsin-like activity assay. *p<0.05 vs. CTL group, one-way ANOVA followed by the Dunnett's test, n=3. B, and C, The levels of GFP-LC3-II were increased in NRVMs by MG132 treatment in a dose- and time-dependent manner. Cultured NRVMs were infected with Ad-GFP-LC3. Three days later, NRVMs were treated with the indicated doses of MG132 for 12 hours (B) or treated with 1μM MG132 for the indicated time courses (C). The cells were then harvested for western blot analyses for the indicated proteins